{"organizations": [], "uuid": "eaf6373dd68bcaaf2c58af747f89afd01fc5649f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-esperion-announces-positive-top-li/brief-esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-added-on-to-a-pcsk9-inhibitor-idUSFWN1R90CK", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.769, "site_type": "news", "published": "2018-03-27T19:43:00.000+03:00", "replies_count": 0, "uuid": "eaf6373dd68bcaaf2c58af747f89afd01fc5649f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-esperion-announces-positive-top-li/brief-esperion-announces-positive-top-line-results-from-phase-2-study-of-bempedoic-acid-added-on-to-a-pcsk9-inhibitor-idUSFWN1R90CK", "ord_in_thread": 0, "title": "BRIEF-Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor", "locations": [], "entities": {"persons": [{"name": "bempedoic", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "negative"}, {"name": "esperion", "sentiment": "negative"}, {"name": "esperion therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA\n* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING\n* ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY\n* ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T19:43:00.000+03:00", "crawled": "2018-03-28T18:42:06.018+03:00", "highlightTitle": ""}